Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Multisensory Room Therapy for Stress and Sensory Regulation in Children With Autism and Their Caregivers

13 novembre 2026 mis à jour par: SERGIO MONTERO NAVARRO

Multidimensional Study of Child and Parental Stress in Autism Spectrum Disorder After a Multisensory Intervention: Biomarkers, Sensory Responses and Clinical Assessment. A Randomised Controlled Trial

The goal of this clinical trial is to learn whether therapy in a multisensory room improves sensory processing, behavioural and attentional regulation and stress in children aged 3 to 12 years with autism spectrum disorder (support level 2-3), and whether it reduces stress in their main caregivers. The main question it aims to answer is: does sensory processing (Sensory Profile 2) change more after 8 weeks of multisensory room therapy than after 8 weeks of standard behavioural therapy? Researchers will also compare executive function, attention and behaviour, parental stress, and stress-related biomarkers in saliva (cortisol, oxytocin and inflammatory interleukins). They will also record physiological stress signals in caregivers (heart rate, skin conductance, breathing and temperature).

Sixty children will be randomly assigned to one of two groups. Children in the first group will receive two individual 45-minute multisensory room sessions per week for 8 weeks. Children in the second group will receive standard behavioural therapy with psychology and speech therapy, without multisensory stimulation. Caregivers will complete questionnaires and give saliva samples before and after the 8-week programme.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

Background. Sensory processing differences are highly prevalent in autism spectrum disorder (ASD) and are associated with anxiety, emotional dysregulation and lower adaptive functioning. Children with ASD show atypical activation of the hypothalamic-pituitary-adrenal axis and elevated pro-inflammatory cytokines. Parents of children with ASD report high parenting stress. Multisensory environments (Snoezelen®) are widely used to support self-regulation, but controlled trials with objective outcomes are scarce.

Design. Randomised, controlled, parallel-group trial with pre-post assessment. Families with a child aged 3-12 years with ASD (support level 2-3) attending the Centre de Teràpia Interfamiliar (Elche, Spain) are randomised 1:1. Randomisation is stratified by age, sex and the primary outcome, in blocks of two, and the sequence is concealed. Outcome assessors are blinded to group allocation; therapists cannot be blinded.

Interventions. Multisensory group: 16 individual 45-minute sessions (2 per week for 8 weeks) in a multisensory room, delivered by occupational therapists trained in multisensory stimulation in ASD. Each session follows a semi-structured protocol: welcome and adaptation (5 min); guided sensory regulation with graded visual, auditory, tactile, vestibular and proprioceptive stimuli (15-20 min); active participation and control of the environment (10-15 min); and closure with return to calm (5 min). Control group: 45-minute sessions of standard behavioural therapy with psychology and speech therapy, under standard lighting, without therapeutic multisensory stimuli and with the same therapist presence.

Assessments. Baseline (T0): child saliva biomarkers; caregiver-reported Sensory Profile 2, BRIEF-P/BRIEF-2, Conners scales and PSI-SF; caregiver saliva and hair biomarkers; and caregiver physiological recording (BIOPAC MP36R). During the intervention (T1): child saliva before and after each session, and a structured observational self-regulation record after each session. After 8 weeks (T2): caregiver-reported scales, caregiver biomarkers and physiological recording. Salivary cortisol, oxytocin, IL-6, IL-1β, IL-17A and TNF-α are analysed by ELISA at Universidad CEU Cardenal Herrera.

Setting and data. The study is conducted at the Centre de Teràpia Interfamiliar (Elche, Spain) in collaboration with the Neurobiology research group of Universidad CEU Cardenal Herrera. Data are pseudonymised and handled in accordance with the GDPR and Spanish Organic Law 3/2018.

Type d'étude

Interventionnel

Inscription (Estimé)

120

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

3 ans à 12 ans (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria (children):

  • Clinical diagnosis of autism spectrum disorder, support level 2 or 3 (DSM-5).
  • Age 3 to 12 years.
  • Attending and registered at the Centre de Teràpia Interfamiliar.
  • Stable therapeutic and pharmacological treatment during the study period.
  • Able to tolerate entering and remaining in the multisensory room.
  • Written informed consent from parents or legal guardians.

Exclusion Criteria (children):

  • Uncontrolled epilepsy.
  • Recent changes in medication.
  • Acute illness at the time of assessment.
  • Severe motor or sensory disability preventing participation in the intervention.
  • Persistent refusal of, or inability to adapt to, the multisensory room.

Inclusion Criteria (caregivers):

  • Adult (18 years or older) main caregiver of an enrolled child.
  • Sufficient cognitive capacity to understand the informed consent.

Exclusion Criteria (caregivers):

  • Acute illness at the time of assessment.
  • Severe motor or sensory disability preventing participation in the assessments.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Multisensory room therapy

Children with ASD receive 8 individual 45-minute sessions (1 per week for 8 weeks) in a multisensory room. Their caregivers complete assessments and provide biological samples.

Semi-structured individual session in a multisensory (Snoezelen®) room delivered by occupational therapists trained in multisensory stimulation in ASD: (1) welcome and adaptation, 5 min, with dim light and no loud sounds; (2) guided sensory regulation, 15-20 min, with graded visual, auditory, tactile, vestibular and proprioceptive stimuli adjusted to the child's profile; (3) active participation and control of the environment, 10-15 min, in which the child chooses or modulates stimuli; (4) closure and return to calm, 5 min. Two sessions per week for 8 weeks.

Autres noms:
  • Snoezelen; Multisensory environment (MSE)
Comparateur actif: Standard behavioural therapy

Children with ASD receive 45-minute sessions of standard behavioural therapy (psychology and speech therapy) without multisensory stimulation, over the same 8-week period. Their caregivers complete the same assessments.

45-minute session with psychology and speech therapy addressing children with ASD support level 2-3, under standard lighting, without therapeutic multisensory stimuli, and with the same therapist presence as the experimental arm.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in sensory hyper-reactivity (Sensory Profile 2, Sensitivity quadrant)
Délai: Baseline and week 8

Sensory Profile 2 - Child form, completed by the main caregiver. Raw score of the Sensitivity quadrant (19 items, each rated from 1 = almost never to 5 = almost always; range 19-95). Higher scores indicate more frequent sensory hyper-reactivity (worse outcome).

Baseline and week 8

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in executive function (Behavior Rating Inventory of Executive Function, BRIEF-P / BRIEF-2)
Délai: Baseline and week 8

Behavior Rating Inventory of Executive Function - Preschool Version (BRIEF-P, ages 3-5) or BRIEF-2 parent form (ages 5-12), completed by the main caregiver. Global Executive Composite raw score (63 items rated 1-3; range 63-189). Higher scores indicate greater executive dysfunction (worse outcome).

Baseline and week 8
Change in emotional and behavioural problems (SENA, Global Problems Index)
Délai: Baseline and week 8

Child and Adolescent Assessment System (SENA), family-report form for ages 3-6 or 6-12, completed by the main caregiver. Global Problems Index, T-score (normative mean 50, SD 10; range of risk 65-69; significative range of risk: >70). Higher scores indicate more emotional and behavioural problems (worse outcome).

Baseline and week 8
Parenting stress (PSI-SF)
Délai: Baseline and week 8

PSI-SF is a 36-item, self-report measure of parenting stress. It includes three subscales: Parental Distress (PD; e.g, "I feel trapped by my responsibilities as a parent", "I feel lonely and without friends"), Parent-Child Dysfunctional Interaction (PCDI; e.g, "Sometimes I feel my child doesn't like me and doesn't want to be close to me", "When I do things for my child I get the feeling that my efforts are not appreciated" ), and Difficult Child (DC; e.g, "My child makes more demands on me than most children", "My child gets upset easily over the smallest thing"). Each subscale consists of 12 items rated from 1 (strongly disagree) to 5 (strongly agree), with subscales scores ranging from 12 to 60. A Total score is calculated by summing the three subscales scores, ranging from 36 to 180. Scores of 90 or above may indicate a clinical level of stress.

Baseline and week 8
Child salivary cortisol (ng/mL)
Délai: Baseline and before/after each session, weeks 1-8

ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of cortisol: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system)

Baseline and before/after each session, weeks 1-8
Child salivary oxytocin (pg/mL)
Délai: Baseline and before/after each session, weeks 1-8

ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of oxytocin: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system)

Baseline and before/after each session, weeks 1-8
Child salivary pro-inflammatory cytokines
Délai: Baseline and before/after each session, weeks 1-8

Salivary IL-6, IL-1β, IL-17A and TNF-α (pg/mL, ELISA).

Baseline and before/after each session, weeks 1-8
Caregiver stress biomarkers - Salivary cortisol (ng/mL)
Délai: Baseline and week 8
Baseline and week 8
Caregiver stress biomarkers - oxytocin (pg/mL)
Délai: Baseline and week 8
Baseline and week 8
Caregiver stress biomarkers - IL-6, IL-1β, IL-17A and TNF-α (pg/mL) (ELISA)
Délai: Baseline and week 8
Baseline and week 8
Caregiver stress biomarkers - hair cortisol (pg/mg)
Délai: Baseline and week 8
Baseline and week 8
In-session self-regulation (observational record)
Délai: After each session, weeks 1-8

Therapist-rated 8-item record (0-3 per item; total 0-24). Higher scores indicate greater self-regulation difficulty.

After each session, weeks 1-8
Heart rate and heart rate variability (LF, HF, LF/HF ratio). BIOPAC MP36R device
Délai: Baseline and week 8

During a recording of about 30 minutes

Baseline and week 8
Galvanic response by means of Skin conductance (SC). micro-siemens or micro-omhios. BIOPAC MP36R device
Délai: Baseline and week 8

During a recording of about 30 minutes

Baseline and week 8
Breathing rate (breaths per minute). BIOPAC MP36R device
Délai: Baseline and week 8

During a recording of about 30 minutes

Baseline and week 8
Skin temperature (ºC). BIOPAC MP36R device
Délai: Baseline and week 8

During a recording of about 30 minutes

Baseline and week 8

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Adverse events
Délai: Weeks 1-8

Number of children with behavioural crises, sensory overload requiring session interruption, or other adverse events, by group.

Weeks 1-8

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

3 janvier 2027

Achèvement primaire (Estimé)

30 mars 2027

Achèvement de l'étude (Estimé)

30 juin 2027

Dates d'inscription aux études

Première soumission

4 novembre 2026

Première soumission répondant aux critères de contrôle qualité

13 novembre 2026

Première publication (Réel)

19 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • CEEI26/863

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Description du régime IPD

Coded data may be shared only for purposes consistent with the study and under confidentiality guarantees; no international transfers are planned.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .